Company intelligence / Profile preview

Aramis Biotechnologies

Quebec City*, Quebec, Canadaaramisbiotechnologies.com ↗

Ownership: Private
Employees: ~51
Development stage: Preclinical

Overview

Aramis Biotechnologies is developing a next-generation plant-based biomanufacturing platform to produce vaccines and therapeutics. Its lead program is a seasonal influenza vaccine currently at the preclinical stage. The company secured key assets from Medicago—including its technology platform and pilot facility—in late 2023. With significant Canadian government investment ($40 million), Aramis aims to advance its influenza vaccine into clinical trials and expand applications of its proprietary plant-derived biologics technology.

Therapeutic areas: Infectious Diseases
Modalities: Plant-based biologics/vaccinesProphylactic vaccines
Industry: Biotech

Partnerships

Government of Canada (major funding partner)Inherits legacy partnerships/assets from Medicago but no direct pharma partnerships disclosed yet.

Beyond the preview

Go deeper on Aramis Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aramis Biotechnologies.

Explore the full profile